A worldwide, exclusive partnership for the development of a therapeutic autoantibody aimed to neutralise interferon-alpha has been signed between the German biotech company ImmunoQure and the French pharmaceutical company Servier. The goal is to advance ImmunoQure’s therapeutic human Interferon-alpha autoantibody through preclinical development up to the clinical phase, that will be directly managed by Servier. The clinical target are diseases such as systemic lupus erythemathosus and Sjögren’s syndrome.

LEAVE A REPLY

Please enter your comment!
Please enter your name here